CRBP — Corbus Pharmaceuticals Holdings Share Price
0.000.00%
Last trade - 00:00- $483.57m
- $376.42m
- 45
- 21
- 71
- 42
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 4.68 | ||
| Price to Tang. Book | 4.68 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -37.47% | ||
| Return on Equity | -59.52% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 36.14 | 3.94 | 0.88 | n/a | n/a | n/a | 3.33 | -100% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Corbus Pharmaceuticals Holdings, Inc. is a precision oncology company with a diversified portfolio. The Company's pipeline is comprised of two experimental drugs targeting solid tumors: CRB-701, which is an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload and CRB-601, which is an anti-integrin monoclonal antibody that blocks the activation of TGFβ expressed on cancer cells. Its pipeline also includes CRB-913, which is a highly peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity. It has in-licensed the intellectual property for CRB-601 from Dr. Stephen Nishimura's laboratory at the University of California, San Francisco. The Company does not own or operate manufacturing facilities and relies on third-party contract manufacturing organizations or licensing partners to supply it with drugs for pre-clinical and clinical studies and commercial activities.
Directors
- Alan Holmer CHM (71)
- Yuval Cohen CEO (58)
- Sean Moran CFO (63)
- Craig Millian COO (53)
- Rachael Brake CSO
- Avery Catlin IND (72)
- Rachelle Jacques IND (50)
- John Jenkins IND (63)
- Peter Salzmann IND (54)
- Last Annual
- December 31st, 2023
- Last Interim
- March 31st, 2024
- Incorporated
- December 18th, 2013
- Public Since
- October 24th, 2014
- No. of Shareholders
- 87
- No. of Employees
- 19
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Capital Market
- Shares in Issue
- 10,686,693
- Address
- 500 River Ridge Drive, NORWOOD, 02062
- Web
- https://www.corbuspharma.com/
- Phone
- +1 6179630103
- Contact
- Sean Moran
- Auditors
- EisnerAmper LLP
Upcoming Events for CRBP
Q3 2024 Corbus Pharmaceuticals Holdings Inc Earnings Release
Similar to CRBP
180 Life Sciences
NASDAQ Capital Market
Abeona Therapeutics
NASDAQ Capital Market
ABVC Biopharma
NASDAQ Capital Market
Acesis Holdings
NASDAQ Capital Market
Achieve Life Sciences
NASDAQ Capital Market
FAQ
What is the Corbus Pharmaceuticals Holdings share price?
As of Today at 20:06 UTC, shares in Corbus Pharmaceuticals Holdings are trading at $42.48. This share price information is delayed by 15 minutes.
How has the Corbus Pharmaceuticals Holdings share price performed this year?
Shares in Corbus Pharmaceuticals Holdings last closed at $42.48 and the price had moved by +441.15% over the past 365 days. In terms of relative price strength the Corbus Pharmaceuticals Holdings share price has outperformed the S&P500 Index by +330.6% over the past year.
What are the analyst and broker recommendations for Corbus Pharmaceuticals Holdings?
The overall consensus recommendation for Corbus Pharmaceuticals Holdings is Strong Buy. You can view the full broker recommendation list by unlocking its StockReport.
What is the Corbus Pharmaceuticals Holdings dividend yield?
Corbus Pharmaceuticals Holdings does not currently pay a dividend.
Does Corbus Pharmaceuticals Holdings pay a dividend?
Corbus Pharmaceuticals Holdings does not currently pay a dividend.
When does Corbus Pharmaceuticals Holdings next pay dividends?
Corbus Pharmaceuticals Holdings does not currently pay a dividend.
How do I buy Corbus Pharmaceuticals Holdings shares?
To buy shares in Corbus Pharmaceuticals Holdings you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Corbus Pharmaceuticals Holdings?
As of the previous close price of $42.48, shares in Corbus Pharmaceuticals Holdings had a market capitalisation of $453.97m.
Where are Corbus Pharmaceuticals Holdings shares listed?
Here are the trading details for Corbus Pharmaceuticals Holdings:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: CRBP
What kind of share is Corbus Pharmaceuticals Holdings?
Based on an overall assessment of its quality, value and momentum Corbus Pharmaceuticals Holdings is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Corbus Pharmaceuticals Holdings share price forecast for 2024?
The analyst consensus target price for shares in Corbus Pharmaceuticals Holdings is $79.33. That is 86.75% above the last closing price of $42.48.
Analysts covering Corbus Pharmaceuticals Holdings currently have a consensus Earnings Per Share (EPS) forecast of -$5.33 for the next financial year.
What is the trend in the Corbus Pharmaceuticals Holdings share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Corbus Pharmaceuticals Holdings. Over the past six months, its share price has outperformed the S&P500 Index by +574.86%.
As of the last closing price of $42.48, shares in Corbus Pharmaceuticals Holdings were trading +93.38% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Corbus Pharmaceuticals Holdings PE Ratio?
The Corbus Pharmaceuticals Holdings PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $42.48.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Corbus Pharmaceuticals Holdings?
Corbus Pharmaceuticals Holdings' management team is headed by:
- Alan Holmer - CHM
- Yuval Cohen - CEO
- Sean Moran - CFO
- Craig Millian - COO
- Rachael Brake - CSO
- Avery Catlin - IND
- Rachelle Jacques - IND
- John Jenkins - IND
- Peter Salzmann - IND